235 related articles for article (PubMed ID: 33144375)
1.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
2. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
[TBL] [Abstract][Full Text] [Related]
3. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
[TBL] [Abstract][Full Text] [Related]
6. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.
Sutherland KA; Mbisa JL; Ghosn J; Chaix ML; Cohen-Codar I; Hue S; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2014 Dec; 69(12):3340-8. PubMed ID: 25096075
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.
Sutherland KA; Mbisa JL; Cane PA; Pillay D; Parry CM
J Gen Virol; 2014 Jan; 95(Pt 1):190-200. PubMed ID: 24172906
[TBL] [Abstract][Full Text] [Related]
10. Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Sutherland KA; Collier DA; Claiborne DT; Prince JL; Deymier MJ; Goldstein RA; Hunter E; Gupta RK
Sci Rep; 2016 Nov; 6():38153. PubMed ID: 27901085
[TBL] [Abstract][Full Text] [Related]
11. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
[TBL] [Abstract][Full Text] [Related]
12. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
[TBL] [Abstract][Full Text] [Related]
14. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.
Knops E; Däumer M; Awerkiew S; Kartashev V; Schülter E; Kutsev S; Brakier-Gingras L; Kaiser R; Pfister H; Verheyen J
J Antimicrob Chemother; 2010 Jul; 65(7):1472-6. PubMed ID: 20430786
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
[TBL] [Abstract][Full Text] [Related]
17. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
18. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
19. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
[TBL] [Abstract][Full Text] [Related]
20. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
